Annual Report 2017

Database for clinical trials


The FPS Public Health and the FAMHP invite you to participate in the public consultation on two clinical trials with the genetically modified medicinal product AVXS-101 from the company AveXis, Inc. The purpose of the trials is to evaluate the safety, tolerability and efficacy of AVXS-101 for the treatment of spinal muscular atrophy. The public consultation runs from 17 October 2018 to 17 November 2018 inclusive.

The FAMHP would like to remind consumers and patients about a recall by Reckitt Benckiser of Durex Natural Feeling Extra Lubricated condoms and Durex Real Feeling latex-free polyisoprene condoms. This is a repeat of a safety alert previously issued by the FAMHP that may have escaped the attention of some consumers and patients.

In 2017, the 460 employees of the FAMHP closed more than 8,000 applications for marketing authorisation for medicines, carried out no less than 2,200 inspections and investigations, analysed more than 10,000 reports of adverse effects, reactions and incidents, and answered more than 250 press questions.

Last updated on 29/06/2017